| Popis: |
Red cell and platelet transfusions are essential in the management of people with haematological malignancies and bone marrow failure disorders. Up to 65% of platelet components and 25% of red cell components issued are given to haematology patients, and most are used in the elderly. As the UK population is ageing, with a predicted doubling in people aged 85 years by 2041, only using red cell and platelet transfusion to those likely to benefit is imperative to minimise side effects, limit costs, and maintain the blood supply. |
